Biotricity (NASDAQ:BTCY) Trading Up 12.6% – Should You Buy?

Biotricity, Inc. (NASDAQ:BTCY) was up 12.6% during trading on Friday . The company traded as high as $0.52 and last traded at $0.45. Approximately 84,123 shares traded hands during trading, an increase of 7% from the average daily volume of 78,566 shares. The stock had previously closed at $0.40.

Biotricity Stock Performance

The company has a market capitalization of $10.19 million, a P/E ratio of -0.26 and a beta of 1.22. The stock has a 50 day moving average price of $0.33 and a 200 day moving average price of $0.66.

Biotricity (NASDAQ:BTCY) last released its earnings results on Monday, August 19th. The company reported ($0.49) EPS for the quarter. The firm had revenue of $3.20 million during the quarter. As a group, sell-side analysts expect that Biotricity, Inc. will post -0.43 earnings per share for the current year.

Institutional Investors Weigh In On Biotricity

A hedge fund recently bought a new stake in Biotricity stock. AE Wealth Management LLC acquired a new position in Biotricity, Inc. (NASDAQ:BTCY) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 97,751 shares of the company’s stock, valued at approximately $88,000. AE Wealth Management LLC owned about 0.45% of Biotricity as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 3.89% of the company’s stock.

About Biotricity

Biotricity, Inc, a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses.